Drug Price Transparency in Medicaid Act of 2019
Official title: To amend title XIX of the Social Security Act to improve transparency and prevent the use of abusive spread pricing and related practices in the Medicaid program.
More subjectsShow fewer subjects
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Referred to the Subcommittee on Health.
Drug Price Transparency in Medicaid Act of 2019
This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions, dispensing fees, and survey participation to be made publicly available.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 5281: Drug Price Transparency in Medicaid Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-HR-5281/
"H.R. 5281: Drug Price Transparency in Medicaid Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-5281/.
H.R. 5281, 116th Cong. (2026), https://openamerica.io/bill/116-HR-5281/.
[H.R. 5281: Drug Price Transparency in Medicaid Act of 2019](https://openamerica.io/bill/116-HR-5281/)